Free Trial
→ You missed yesterday's deadline… (From Behind the Markets) (Ad)tc pixel
NYSEAMERICAN:OGEN

Oragenics Q4 2025 Earnings Results & Report

Oragenics logo
$0.20 -0.15 (-42.59%)
Closing price 11/13/2026 04:10 PM Eastern
Extended Trading
$0.20 0.00 (0.00%)
As of 11/13/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Oragenics reported Q4 2025 earnings on March 16, 2026. The company reported EPS of $0.60.

Research:ProfileEarnings History

Earnings Announcement Details

Quarter
Q4 2025
Report Date
Time
Before Market Opens

Oragenics EPS Results

Actual EPS
$0.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Oragenics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Oragenics Q4 2025 Earnings FAQ

Oragenics (NYSEAMERICAN:OGEN) reported earnings of $0.60 per share for Q4 2025. The report was announced on Monday, March 16, 2026.

Oragenics Earnings Headlines

Oragenics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026
November 13 at 1:43 PM  |  marketscreener.comM
Oragenics Receives NYSE American Approval of Compliance Plan and Extension Through February 2028
November 12 at 4:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/12/3402141/0/en/oragenics-receives-nyse-american-approval-of-compliance-plan-and-extension-through-february-2028.html
A free stock pick, from me to you
Elon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.tc pixel
November 14 at 1:00 AM  |  Behind the Markets (Ad)
Oragenics (NYSEAMERICAN:OGEN) Shares Climb 0.1% - Time to Buy?
November 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31183560
Oragenics Inc
October 22, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/ogen-oragenics-inc/vitals
Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum
September 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/16/3363159/0/en/oragenics-chief-medical-officer-to-present-at-ipac-rs-2026-nasal-innovation-forum.html
See More Oragenics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oragenics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oragenics and other key companies, straight to your email.

About Oragenics

Oragenics (NYSEAMERICAN:OGEN) is a biotechnology company focused on developing intranasal medicines for neurological disorders. Its approach is designed to deliver drug candidates through the nasal passage directly to the brain, with the goal of addressing conditions for which conventional drug-delivery methods may be limited.

The company’s lead product candidate is ONP-002, an intranasal therapy being developed for the treatment of concussion and traumatic brain injury. Oragenics has also pursued additional preclinical programs targeting neurological and neurodegenerative diseases, although the development status and scope of these programs may change as the company advances its pipeline.

Founded in 1996 and headquartered in Florida, Oragenics historically worked on oral-care and antibiotic technologies, including products based on lantibiotics and beneficial bacteria. The company subsequently shifted its primary focus toward intranasal therapeutics for central nervous system disorders and has conducted its development activities principally in the United States.

View Oragenics Profile
Earnings Tools